Article

Genentech letter warns of stroke risk with ranibizumab

South San Francisco-Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD).

Related Videos
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Image credit: AdobeStock/IllustrateMuse
February 5th 2025

Tuning out anxiety: the role of music in cataract surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Image credit: Mercy Ships
February 4th 2025

Mercy Ships delivers a lifeline for eye health in Africa’s remote communities

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study investigates neurological impact of diabetic vitreous hemorrhage
February 4th 2025

Study investigates neurological impact of diabetic vitreous hemorrhage

MERIT acquires OSOD to enhance ophthalmic drug development
February 4th 2025

MERIT acquires OSOD to enhance ophthalmic drug development

© 2025 MJH Life Sciences

All rights reserved.